Skip to main content
. Author manuscript; available in PMC: 2024 Feb 21.
Published in final edited form as: Lancet Diabetes Endocrinol. 2021 Sep 1;9(10):708–724. doi: 10.1016/S2213-8587(21)00170-4

Figure 3: Current status of stem-cell derived insulin-producing cells.

Figure 3:

A. The first clinical trial using stem-cell derived insulin-producing cells for diabetes treatment (ClinicalTrials.gov Identifier: NCT04678557) uses pancreatic progenitors that will mature in vivo into islet-like structures. B. Current differentiation protocols are focused on improving the differentiation of pancreatic progenitors into beta-like cells in vitro. C. We believe that the goal of future differentiation protocols will be to generate islet-like organoids with alpha-, beta- and delta-cells that are highly vascularised pre- or rapidly post-transplantation.